Építés alatt – nem éles oldal
Belépés
Leállítva3. fázis

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

A legfontosabb adatok

Ki végzi
Biogen
Hol
Japán12 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
3. fázis
Résztvevők
21 fő vett részt
Kezdés
2022. ápr. 26.
Befejezés
2024. máj. 27.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Natalizumab
A regiszteradat frissítve
2025. november 25.
Miért állt le
Due to sponsor decision, not for efficacy or safety reasons.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Must have had a diagnosis of RRMS, as defined by the revised 2017 McDonald's criteria. All other possible neurologic diagnoses must have been reasonably excluded by means of laboratory and/or imaging studies, in the opinion of the investigator
  • Must have had an EDSS score between 0.0 and 5.5, inclusive
  • Must have had screening MRI or documentation of an MRI within the participant's medical record within 12 months of the screening visit that revealed 3 or more T2 hyperintense lesions consistent with MS
  • Was born in Japan, and biological parents and grandparents were of Japanese origin

Ki nem vehet részt

  • Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 14 days prior to Screening, between screening and baseline visit, or at baseline visit, including but not limited to a fever (temperature > 37.5 degrees Celsius [°C]), new and persistent cough, breathlessness, or loss of taste and/or smell
  • Have close contact within 14 days prior to Day 1 with a SARS-CoV-2 positive individual
  • An MS exacerbation (relapse) within 30 days prior to enrolment or, in the opinion of the investigator, the participant not having stabilized from a previous relapse prior to enrolment (Day 1)
  • Previous exposure to natalizumab; Note: Other protocol specified Inclusion/Exclusion criteria may apply
  • Diagnosis of primary progressive MS or secondary progressive MS
  • The participant is unable to have a brain MRI scan (e.g., a participant with a metal clip to repair a cerebral aneurysm)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this study is to evaluate the efficacy of natalizumab 300 milligrams (mg) subcutaneous (SC) every 4 weeks (Q4W) administrations up to 24 weeks in Japanese participants with relapsing-remitting multiple sclerosis (RRMS).

A teljes eredeti leírásKevesebb

The secondary objectives of the study are to evaluate other clinical and magnetic resonance imaging (MRI) measures of efficacy of natalizumab 300 mg SC Q4W administrations in Japanese participants with RRMS, to evaluate the safety, tolerability, and immunogenicity of natalizumab 300 mg SC Q4W administrations up to 48 weeks in Japanese participants with RRMS, to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of natalizumab 300 mg SC Q4W administrations up to 24 weeks and for an additional 24 weeks in Japanese participants with RRMS.

A vizsgálat csoportja

  • NatalizumabA vizsgált kezelés

    Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered to Japanese Participants With Relapsing-Remitting Multiple Sclerosis Via a Subcutaneous Route of Administration
A regiszteradat frissítve
2025. november 25.